Differentiated Thyroid Cancer Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Differentiated Thyroid Cancer Therapeutics Market is Segmented by Therapy (Chemotherapy, Targeted Therapy, Thyroid Stimulating Hormone Suppression (THS), and Other Therapies) and Geography.

Differentiated Thyroid Cancer Therapeutics Market Snapshot

Differentiated Thyroid Cancer Therapeutics Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 21.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The differentiated thyroid cancer (DTC) therapeutics market is expected to register a CAGR of 21.5% during the forecast period. The major factors attributing to the growth of the market are a rise in the incidence of papillary thyroid cancer, which is the most common type of thyroid cancer, accounting for about 80% of all cases. DTC typically doesn't cause any signs or symptoms early in the disease, which results in the development of lumps (nodule) on the neck area, causing difficulties in swallowing, and throat pain, and swollen lymph nodes in the neck.

According to the American Society of Clinical Oncology (ASCO), in 2019, approximately 14,260 men and 37,810 women in the United States were diagnosed with thyroid cancer. It is the most common cancer in women between 20 to 34 years of age, and women are more likely to develop thyroid cancer than men. Furthermore, a rise in government initiatives to control the healthcare burden and growing awareness regarding thyroid cancer treatment options are driving the DTC therapeutics market.

Scope of the Report

Thyroid cancer is a type of cancer that develops in the thyroid gland and can spread to other parts of the body. The thyroid gland produces hormones that regulate blood pressure, heart rate, energy metabolism, and body temperature. DTC is classified as Follicular thyroid cancer and papillary thyroid cancer along with Hurthle cell carcinoma (HCC). HCC is a cancer that arises from a specific type of follicular cell. As per the scope of the report, the DTC therapeutics market is segmented by types of therapies used in the treatment.

By Therapy
Targeted Therapy
Thyroid Stimulating Hormone Suppression (THS)
Other Therapies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Chemotherapy Segment is Expected to Hold a Major Market Share in the Differentiated Thyroid Cancer Therapeutics Market

  • The chemotherapy segment holds a significant market share in the DTC therapeutics market over the forecast period. The dominance is owing to increased use of drugs like doxorubicin, cisplatin, and others as standard treatment. Huge demand can be attributed to the use of combinational drugs and their proven efficiency in preventing cancer progression. These combination drugs reduce the development of drug resistance, which is expected to fuel the market.
  • On the other hand, targeted therapy is anticipated to grow at the highest CAGR. The lucrative growth is due to their usage when cancer is progressing. Also, these targeted drugs act differently on thyroid cancer than standard chemotherapy drugs. These agents block tumors from forming new blood vessels and target some of the proteins which increase the growth of cancer cells. The lesser side effects compared to chemotherapy is expected to boost the growth of the segment.
Differentiated Thyroid Cancer Therapeutics Market

North America is Expected to Hold a Significant Share in the Market and it is Expected to do the Same in the Forecast Period

North America is expected to hold a major market share in the global differentiated thyroid cancer therapeutics market due to rising incidences of PTC, increased mortality rate in this region. For instance, the American Society of Clinical Oncology (ASCO), PTC covers more than 85% of overall thyroid cancers in the United States. Also, according to estimates published by the Thyroid Cancer Survivors' Association, thyroid cancer affects nearly 52,890 new cases in the United States in 2020, which increased from 52,070 cases in the year 2019. Furthermore, the presence of top pharma and biotech companies that are involved in the development of new therapies and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Differentiated Thyroid Cancer Therapeutics Market

Competitive Landscape

The differentiated thyroid cancer therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Bayer AG, Merck Co Inc., Jerome Stevens Pharmaceuticals Inc., Pfizer Inc., Curium SAS.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Thyroid Cancer

      2. 4.2.2 Rising Government Funds and Reimbursement Policies

    3. 4.3 Market Restraints

      1. 4.3.1 Introduction of Generic Products Due to Patent Expiry of the Branded Drugs

      2. 4.3.2 Lack of Awareness about Treatment Options for Thyroid Cancer

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Therapy

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Thyroid Stimulating Hormone Suppression (THS)

      4. 5.1.4 Other Therapies

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Jubilant Life Sciences (Jubilant DraxImage)

      2. 6.1.2 Rosatom State Corporation (JSC Isotope)

      3. 6.1.3 Curium SAS


      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 IBSA Group (IBSA Pharma Inc.)

      7. 6.1.7 Mylan NV

      8. 6.1.8 Sanofi (Genzyme Corporation)

      9. 6.1.9 Exelixis Inc.

      10. 6.1.10 Bayer AG

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Differentiated Thyroid Cancer Therapeutics Market market is studied from 2018 - 2026.

The Differentiated Thyroid Cancer Therapeutics Market is growing at a CAGR of 21.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck Co Inc, Bayer AG, Jerome Stevens Pharmaceuticals Inc, Pfizer Inc, Curium SAS are the major companies operating in Differentiated Thyroid Cancer Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!